Portal de Periódicos da CAPES

Antagonism of the Stat3–Stat3 Protein Dimer with Salicylic Acid Based Small Molecules

2011; Wiley; Volume: 6; Issue: 8 Linguagem: Inglês

10.1002/cmdc.201100194

1860-7187

Steven Fletcher, Brent D. G. Page, Xiaolei Zhang, Peibin Yue, Zhihua Li, Sumaiya Sharmeen, Jagdeep Singh, Wei Zhao, Aaron D. Schimmer, Suzanne Trudel, James Turkson, Patrick T. Gunning,

PI3K/AKT/mTOR signaling in cancer

Abstract More than 50 new inhibitors of the oncogenic Stat3 protein were identified through a structure–activity relationship (SAR) study based on the previously identified inhibitor S3I‐201 (IC 50 =86 μ M , K i >300 μ M ). A key structural feature of these inhibitors is a salicylic acid moiety, which, by acting as a phosphotyrosine mimetic, is believed to facilitate binding to the Stat3 SH2 domain. Several of the analogues exhibit higher potency than the lead compound in inhibiting Stat3 DNA binding activity, with an in vitro IC 50 range of 18.7–51.9 μ M , and disruption of Stat3–pTyr peptide interactions with K i values in the 15.5–41 μ M range. One agent in particular exhibited potent inhibition of Stat3 phosphorylation in both breast and multiple myeloma tumor cells, suppressed the expression of Stat3 target genes, and induced antitumor effects in tumor cells harboring activated Stat3 protein.